Search details
1.
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
Mult Scler
; 25(4): 565-573, 2019 04.
Article
in English
| MEDLINE | ID: mdl-29521573
2.
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
Mult Scler
; 23(1): 94-105, 2017 01.
Article
in English
| MEDLINE | ID: mdl-27003945
3.
US Food and Drug Administration Perspectives on Clinical Mass Spectrometry.
Clin Chem
; 62(1): 41-7, 2016 Jan.
Article
in English
| MEDLINE | ID: mdl-26553791
4.
Quantitative Proteomic Verification of Membrane Proteins as Potential Therapeutic Targets Located in the 11q13 Amplicon in Cancers.
J Proteome Res
; 14(9): 3670-9, 2015 Sep 04.
Article
in English
| MEDLINE | ID: mdl-26151158
5.
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
N Engl J Med
; 366(11): 1000-9, 2012 Mar 15.
Article
in English
| MEDLINE | ID: mdl-22417253
6.
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
J Neurol Neurosurg Psychiatry
; 85(8): 851-8, 2014 Aug.
Article
in English
| MEDLINE | ID: mdl-24029546
7.
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
Neurology
; 102(9): e209357, 2024 May 14.
Article
in English
| MEDLINE | ID: mdl-38648580
8.
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
BMC Neurol
; 13: 80, 2013 Jul 11.
Article
in English
| MEDLINE | ID: mdl-23841877
9.
Variability in detection and quantification of interferon ß-1b-induced neutralizing antibodies.
J Neuroinflammation
; 9: 129, 2012 Jun 15.
Article
in English
| MEDLINE | ID: mdl-22703536
10.
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
Ann Neurol
; 70(6): 897-912, 2011 Dec.
Article
in English
| MEDLINE | ID: mdl-22190364
11.
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
Mult Scler
; 18(2): 181-95, 2012 Feb.
Article
in English
| MEDLINE | ID: mdl-21952094
12.
Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology.
Neurol Clin Pract
; 11(4): 352-357, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-34484933
13.
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study.
BMJ Open
; 10(10): e038861, 2020 10 20.
Article
in English
| MEDLINE | ID: mdl-33082194
14.
Enzyme activity--it's all about image.
Trends Cell Biol
; 14(1): 29-35, 2004 Jan.
Article
in English
| MEDLINE | ID: mdl-14729178
15.
Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies.
Mult Scler Relat Disord
; 36: 101335, 2019 Nov.
Article
in English
| MEDLINE | ID: mdl-31557679
16.
Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Neurology
; 93(13): 584-594, 2019 09 24.
Article
in English
| MEDLINE | ID: mdl-31462584
17.
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Lancet Neurol
; 7(10): 903-14, 2008 Oct.
Article
in English
| MEDLINE | ID: mdl-18789766
18.
Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Clin Ther
; 30(6): 1102-12, 2008 Jun.
Article
in English
| MEDLINE | ID: mdl-18640466
19.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Lancet Neurol
; 17(5): 405-415, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29545067
20.
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
Neurology
; 89(15): 1584-1593, 2017 Oct 10.
Article
in English
| MEDLINE | ID: mdl-28916537